Saito M, Mori A, Kajikawa S, Yokoyama E, Kanaya M, Izumiyama K, Morioka M, Kondo T, Tanei ZI, Shimizu A. Helicobacter pylori eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis. World J Clin Cases 2023; 11(27): 6424-6430 [PMID: 37900236 DOI: 10.12998/wjcc.v11.i27.6424]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Makoto Saito, Akio Mori, Sayaka Kajikawa, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Masanobu Morioka, Takeshi Kondo, Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan
Zen-Ichi Tanei, Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, Japan
Ai Shimizu, Department of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Hokkaido, Japan
Author contributions: Saito M designed this study; Tanei ZI and Shimizu A involved in pathological procedure; all authors made substantial contributions to acquisition of data, or analysis and interpretation of data; took part in drafting the article; and agree to be accountable for all aspects of the work.
Institutional review board statement: This study was conducted in accordance with the World Medical Association Declaration of Helsinki, and this study was reviewed and approved by the Aiiku Hospital Clinical Research Review Board (Sapporo).
Informed consent statement: All patients provided written informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: June 23, 2023 Peer-review started: June 23, 2023 First decision: August 9, 2023 Revised: August 11, 2023 Accepted: August 29, 2023 Article in press: August 29, 2023 Published online: September 26, 2023 Processing time: 78 Days and 15.7 Hours
Abstract
BACKGROUND
Unlike the already established effect of Helicobacter pylori (H. pylori) eradication on gastric mucosa-associated lymphoid tissue (MALT) lymphoma, its therapeutic effect on primary gastric diffuse large B-cell lymphoma (DLBCL) is still unclear.
AIM
To clarify the efficacy of H. pylori eradication treatment for primary gastric DLBCL.
METHODS
We reported on 3 new cases, and added them to 3 previously reported cases. We analyzed the usefulness of H. pylori eradication treatment for gastric DLBCL for a total of 6 cases at our center.
RESULTS
Of the 6 patients (27-90 years old, 3 males and 3 females), all 3 patients with single lesions (one transformed from MALT lymphoma) achieved complete remission (CR) after H. pylori eradication. Regarding the 2 newly reported cases, CR was maintained for more than 6 years with eradication treatment alone. In contrast, none of the 3 patients with 2 lesions achieved CR. In 1 newly reported case, endoscopic CR was achieved in one lesion, while stable disease was obtained in the other lesion. Two patients with progressive disease responded to standard chemotherapy ± radiation and remained in CR for more than 6 years.
CONCLUSION
We believe it is worthwhile to attempt H. pylori eradication for elderly patients with primary gastric DLBCL in a single lesion with a small tumor burden.
Core Tip: Unlike the already established effect of Helicobacter pylori (H. pylori) eradication on gastric mucosa-associated lymphoid tissue lymphoma, its therapeutic effect on primary gastric diffuse large B-cell lymphoma (DLBCL) is not clear. Previously, we reported 1 successful case and 2 failed cases. We report here on 3 new cases, and we considered a total of 6 cases. Three patients with a single lesion achieved complete remission, in contrast, 3 patients with multiple lesions persisted or progressed. We believe it is worthwhile to attempt H. pylori eradication for an elderly patient with a single lesion and a small tumor burden of primary gastric DLBCL.
